Physician profile
Allyson Riggs
NPI 1720691470
$770.74
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $698 · 2022: $72.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.27 | 2021-2022 | |
| Pfizer INC. | $114.49 | 2021 | |
| Abbvie INC. | $79.12 | 2021-2022 | |
| Amgen INC. | $69.38 | 2021 | |
| Glaxosmithkline, LLC. | $60.11 | 2021 | |
| Amarin Pharma, INC. | $46.59 | 2021 | |
| Lilly USA, LLC | $43.72 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $41.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.10 | 2021 | |
| Eisai INC. | $25.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Riggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.